Vanguard Capital Management
TXMD icon

Vanguard Capital Management’s TherapeuticsMD TXMD Stock Holding History

Vanguard Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$782K Hold
353,697
– – ﹤0.01% 3641
2026
Q1 		$714K Buy
+353,697
New +$795K ﹤0.01% 3616

Other funds holding TXMD

TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Capital Management's TXMD Position: Q2 2026 in Review

Vanguard Capital Management held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 353,697 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #3641.

Vanguard Capital Management first reported a position in TXMD in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Vanguard Capital Management held 353,697 shares of TherapeuticsMD worth $782K as of Q2 2026.
  • Vanguard Capital Management left its TherapeuticsMD share count unchanged in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3641 holding.
  • Vanguard Capital Management first reported a position in TherapeuticsMD in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.